Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on X:
“Cases like this highlight the need for true tissue‑agnostic approvals. DLL3 expression shows up well beyond small cell lung cancers and our trial design and regulatory frameworks should follow the biology. Biomarker‑driven, not tissue‑ bound.
Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment, JCO Precision Oncology.”
Title: Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment
Authors: Timothy Schieber, Jacob Hobbs, Jessica Campaign-Mauser, Emma J. Jones, Alexander Olinger, Bryce Bortka, Beth Gustafson, Sarah Blocker, Diana Kim, Sanjana Mullangi, Manidhar Reddy Lekkala, Rahul Parikh, Chao Huang, Prakash Neupane, Haoran Li
Read The Full Article
Other articles featuring Vivek Subbiah on OncoDaily.